Physician profile
Heather E Jackson
NPI 1699308569
$2,954.32
in general payments reported to CMS, 2019-2025
23 companies · $2,391 in 2025
The $2,391 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.91 · 2022: $12.38 · 2023: $129 · 2024: $409 · 2025: $2,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Travel and Lodging: $1,107 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.37 |
| Travel and Lodging | $1,107.10 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,517.23 | 2025 | |
| Madrigal Pharmaceuticals | $316.66 | 2024-2025 | Rezdiffra |
| Abbvie INC. | $312.88 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.94 | 2023 | Relistor |
| Collegium Pharmaceutical, INC. | $73.50 | 2021-2024 | Belbuca, Xtampza |
| Lundbeck LLC | $72.83 | 2024-2025 | Vyepti, Rexulti |
| Regeneron Healthcare Solutions, INC. | $61.82 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $51.24 | 2025 | Tremfya |
| Ucb, INC. | $47.59 | 2025 | Rystiggo, Bimzelx |
| Sk Life Science, INC. | $43.67 | 2025 | |
| Ardelyx, INC. | $42.89 | 2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $42.75 | 2025 | Austedo Xr |
| Argenx US, INC. | $41.18 | 2025 | Vyvgart Hytrulo |
| Pfizer INC. | $39.99 | 2025 | |
| Lilly USA, LLC | $39.78 | 2025 | Omvoh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.29 | 2024-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $21.94 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $20.09 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $18.99 | 2025 | Zenpep |
| Boston Scientific Corporation | $18.64 | 2023 | Wavewriter Alpha Prime 16 |
| Amneal Pharmaceuticals LLC | $16.04 | 2025 | Crexont |
| Intercept Pharmaceuticals, INC. | $16.00 | 2024 | |
| Amgen INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.